Search Results

Character Biosciences, a drug discovery and development company leveraging human genetics and medical imaging-based machine learning to target disease progression, announced the appointment of Laura Carter, Ph.D. as Chief Scientific Officer.

Neurocrine Biosciences today announced that it will present CAHtalyst™ Adult Phase 3 clinical study baseline characteristics for adults with congenital adrenal hyperplasia.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including baseline characteristics data from its CAHtalyst™ Program.

Aadi Bioscience expects that pipeline adjustments and the workforce reduction will extend its cash runway into at least the second half of 2026.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for children and adolescents with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency enrolled in the study, along with CAHtalog™ Registry data assessing glucocorticoid treatment patterns in pediatric and adult patients with CAH.

Precision BioSciences, Inc. today announced its addition to the Russell Microcap® Index.

Genflow Biosciences Strengthens Pre-Clinical Efforts with FDA Guidance and CDMO and CRO Selection

Precision BioSciences, Inc. today announced that members of management will participate in the following upcoming investor conferences in June.

Octave ® Bioscience, Inc. today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), wishes to announce that